Noble Financial Estimates Zomedica FY2024 Earnings

Zomedica Corp. (NYSEAMERICAN:ZOMFree Report) – Stock analysts at Noble Financial issued their FY2024 earnings per share estimates for shares of Zomedica in a research note issued to investors on Monday, November 11th. Noble Financial analyst R. Leboyer forecasts that the company will post earnings of ($0.05) per share for the year. Noble Financial has a “Strong-Buy” rating on the stock. The consensus estimate for Zomedica’s current full-year earnings is ($0.05) per share. Noble Financial also issued estimates for Zomedica’s Q4 2024 earnings at ($0.01) EPS, Q1 2025 earnings at ($0.01) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.03) EPS, FY2026 earnings at ($0.03) EPS and FY2027 earnings at ($0.03) EPS.

Zomedica Stock Performance

ZOM opened at $0.14 on Thursday. The company has a market cap of $132.29 million, a PE ratio of -2.29 and a beta of 1.06. Zomedica has a 52-week low of $0.12 and a 52-week high of $0.23.

Institutional Investors Weigh In On Zomedica

Several hedge funds have recently bought and sold shares of ZOM. Virtu Financial LLC grew its stake in shares of Zomedica by 1,585.0% during the 1st quarter. Virtu Financial LLC now owns 168,773 shares of the company’s stock valued at $25,000 after purchasing an additional 158,757 shares during the period. Jane Street Group LLC purchased a new position in shares of Zomedica in the third quarter worth approximately $25,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in Zomedica by 41.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 948,300 shares of the company’s stock valued at $139,000 after buying an additional 276,100 shares during the last quarter. Institutional investors own 8.95% of the company’s stock.

About Zomedica

(Get Free Report)

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.

See Also

Earnings History and Estimates for Zomedica (NYSEAMERICAN:ZOM)

Receive News & Ratings for Zomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica and related companies with MarketBeat.com's FREE daily email newsletter.